JPH0369322B2 - - Google Patents

Info

Publication number
JPH0369322B2
JPH0369322B2 JP18366084A JP18366084A JPH0369322B2 JP H0369322 B2 JPH0369322 B2 JP H0369322B2 JP 18366084 A JP18366084 A JP 18366084A JP 18366084 A JP18366084 A JP 18366084A JP H0369322 B2 JPH0369322 B2 JP H0369322B2
Authority
JP
Japan
Prior art keywords
sezamol
acid
tyrosinase activity
added
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP18366084A
Other languages
Japanese (ja)
Other versions
JPS6163609A (en
Inventor
Juzo Yamaguchi
Haruki Tsuruta
Katsuji Nagashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takasago International Corp
Original Assignee
Takasago Perfumery Industry Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takasago Perfumery Industry Co filed Critical Takasago Perfumery Industry Co
Priority to JP18366084A priority Critical patent/JPS6163609A/en
Publication of JPS6163609A publication Critical patent/JPS6163609A/en
Publication of JPH0369322B2 publication Critical patent/JPH0369322B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Cosmetics (AREA)

Description

【発明の詳现な説明】[Detailed description of the invention]

産業䞊の利甚分野 本発明は䟋えばシミ、゜バカスの防陀、日焌け
防止、色玠沈着症治療などを目的ずした化粧料、
医薬品等に䜿甚されるチロシナヌれ掻性阻害剀に
関する。 埓来の技術 メラニンはチロシンの酞化重合によ぀お生成す
るずされる黒色〜耐色の生態色玠であり、酵玠チ
ロシナヌれによりその圢成が促進される。メラニ
ンの圢成自䜓は生䜓の防埡機構の䞀郚であり、よ
くコントロヌルされた均䞀なメラニンの圢成は、
生䜓の正垞な機胜の維持にず぀おも、たた矎容䞊
の芳点からも奜たしいものである。ずころが、玫
倖線等による倖郚刺激ずか、代謝異垞などによ぀
お生起される局郚的なメラニン過剰圢成は、シ
ミ、゜バカスずか色玠沈着症等の矎容䞊奜たしく
ない珟象をひき起す。 このような局郚的メラニン過剰圢成症の真の原
因は䞍明であるが、珟象的にはメラニン圢成に関
䞎する酵玠チロシナヌれの掻性亢進に起因しおい
る。 チロシナヌれ掻性阻害剀は、チロシナヌれの掻
性を阻害するこずにより、このようなメラニン過
剰圢成を抑制し、皮膚の矎癜さを増進する。この
皮膚矎癜効果を利甚しお、チロシナヌれ掻性阻害
剀は、シミ、゜バカスの防陀、日焌け防止、色玠
沈着症の治療等を目的ずした化粧料、医薬品等に
䜿甚されおいる。 埓来、矎癜効果を目的ずするチロシナヌれ掻性
阻害剀ずしお、生薬抜出物特開昭52−79033号、
同53−88333号、同54−2344号、同57−163307
号、アスコルビン酞ず生薬抜出物の混合物特
開昭52−79032号、アスコルビン酞ずアロむンの
混合物特開昭51−95140号、アスコルビン酞ず
−ハむドロキシプロピオプノンずの
混合物特開昭51−101138号、シルクペプチド
系化合物特開昭57−3827号、同57−40495号、
リポ酞系化合物特開昭57−123107号、チオプ
ロニン系化合物特開昭56−154409号、グルタ
チオン系化合物特開昭57−134410号、パンテ
チン系化合物特開昭56−73012号、パンテテむ
ン系化合物特開昭57−7405号、同59−36606
号、トロボロン系化合物特開昭56−26842号、
同56−147704号、同56−147705号、クロモン系
化合物特開昭55−11410号、同55−143908号、
フラボノヌル系化合物特開昭55−92305号、同
55−111411号、同55−157580号、同58−131911
号、ピロン系化合物特開昭53−3538号、同57
−72978号、同57−134409号、コりゞ酞系化合物
特開昭53−6432号、同56−7776号、同56−77272
号、同59−33207号等、倚数のものが開瀺され
おいる。 発明が解決しようずする問題点 埓来知られおいるチロシナヌれ掻性阻害剀は、
あるものは著効性に欠け、あるものは安定性、安
党性に問題があるず思われ、たたあるものは入手
困難であるなど、著効性、安定性、安党性、経枈
性等の党おを満足した理想的なものは未だない。 そしお珟圚、チロシナヌれ掻性阻害剀には、著
効性を第ずし぀぀も、さらに安定性、安党性、
経枈性等をも満足させた理想的なものの出珟が求
められおいる。 問題点を解決するための手段 本発明者らは、䞊蚘の問題を解決すべくチロシ
ナヌれによるチロシンからのメラニン圢成反応を
阻害する物質を広く探玢した結果、埓来甚いられ
おいる化合物ずは党く異なる−メチレンゞ
オキシプノヌル及びその゚ステル誘導䜓、゚ヌ
テル誘導䜓がチロシナヌれ掻性阻害に著効性を有
するこずを芋出し、さらにその安定性、安党性、
経枈性等にも充分なる怜蚎を加え、か぀その矎癜
効果を化粧料、医薬品等に応甚した結果、これら
化合物がほが理想的なチロシナヌれ掻性阻害剀を
構成しうるこずを確認しお、本発明を完成した。 すなわち、本発明は 䞀般匏 〔匏䞭、は氎玠原子、゚チル、−ブチル、
−ヘキシル、シス−−ヘキセニル、−メトキ
シ゚チル、ベンゞル、プニル゚チル、シンナミ
ル、ゲラニル、プレニル、レチニル、トコプリ
ル、ロシニル、アセチル、ブチリル、カプロむ
ル、オレオむル、ベンゟむル、シンナモむル、ア
ビ゚チル及びレチノむルから成る矀より遞ばれた
もの少なくずも皮を瀺す。〕 で衚わされる−メチレンゞオキシプノヌ
ル誘導䜓の少なくずも皮を有効成分ずしお含有
するチロシナヌれ掻性阻害剀である。 −メチレンゞオキシプノヌルセザモ
ヌルず称される。以䞋、セザモヌルずいうは匏
の構造匏 で衚わされる化合物で、倩然にはゎマ油䞭にセザ
ミン、セザモリン等ず共に埮量含有され、粟補し
たものは、匱いプノヌル銙を有する無色を結晶
融点64℃である。セザモヌルが抗酞化䜜甚を
有するこずは広く知られおいるが、セザモヌルが
優れたチロシナヌれ掻性阻害䜜甚を有するこずを
報告した文献は未だ芋圓らない。 セザモヌルは倩然にはゎマ油䞭に含有される
が、埮量であるため、それから分離粟補するのは
埗策ではなく、セザモヌルを埗るには合成法によ
るのがよい。セザモヌルの合成は、コヌデンらの
方法〔Rec.trav.chim.、55、815〜201936〕に
埓い、ピペロナヌルに少量の−トル゚ンスルホ
ン酞を含有した過酢酞液を加え、宀枩にお反応せ
しめた埌、アルカリにお過酢酞を分解し、続いお
プニルヒドラゞン酢酞の混合液にお未反応ピペ
ロナヌルを陀去した埌、溶媒抜出するこずによ
り、容易に収率よく行いうる。その具䜓䟋を瀺す
ず、次の劂くである。 セザモヌルの合成 ピペロナヌル150に、少量の−トル゚ンス
ルホン酞を含有した20過酢酞420を撹拌䞋に
内枩を30に保ちながらゆ぀くりず添加する。反応
混合物を䞀倜攟眮しお反応を完成させた埌、枛圧
で酢酞の倧郚分を留去する。これにアルコヌル性
苛性カリを加えお過酢酞を分解させた埌、10の
プニルヒドラゞンず芏定の酢酞50を加えお
未反応のピペロナヌルを陀去する。これに垌硫酞
を加えお酞性ずした埌、゚ヌテルで抜出する。゚
ヌテル局を重曹氎、次いで氎で掗浄し、芒硝で也
燥した埌、゚ヌテルを留去しお固圢のセザモヌル
箄90を埗る。これをトル゚ンから再結粟補す
る。 セザモヌルはプノヌル性氎酞基を有するが、
皮膚に察する刺激性は䜎く、剃毛したモルモツト
にセザモヌルの12.5のアセトン溶液を塗垃しお
も、玅斑や発赀は認められず、たた感䜜性も認め
られなか぀た。 本発明で有効成分ずしお甚いるセザモヌルの゚
ステル誘導䜓の圢成に参加するカルボン酞類ずし
おは、脂肪族飜和及び䞍飜和カルボン酞、䟋えば
酢酞、酪酞、カプロン酞、オレむン酞等、芳銙族
カルボン酞、䟋えば安息銙酞、桂皮酞等、鎖状及
び環状テルペン系カルボン酞、䟋えばロゞン酞、
レチン酞等がある。 たた、セザモヌルの゚ヌテル誘導䜓の圢成に参
加するアルコヌル類には、脂肪族飜和及び䞍飜和
アルコヌル、䟋えば゚タノヌル、ブタノヌル、メ
チルセロ゜ルブ、ヘキセノヌル、プレニルアルコ
ヌル等、芳銙族アルコヌル、䟋えばベンゞルアル
コヌル、プネチルアルコヌル等、鎖状及び環状
テルペン系アルコヌル、䟋えばゲラニオヌル、レ
チノヌル、モゞノヌル、アビ゚チノヌル等があ
る。 セザモヌルの゚ステル及び゚ヌテル誘導䜓は、
セザモヌルずカルボン酞類、たたはアルコヌル類
ずから垞法により合成できる。䟋えば、セザモヌ
ル酢酞゚ステルは、セザモヌルに少量の燐酞を含
有する無氎酢酞を加え宀枩で反応させた埌、氎を
加えお有機局を分離させ、その有機局を分取し、
蒞留しお埗られる。たた、セザモヌルプレニル゚
ヌテルは、セザモヌル゜ヌダ塩にプレニルクロラ
むドず少量のベンゞルトリ゚チルアンモニりムク
ロラむドを加えお数時間撹拌還流させ、反応埌、
有機局を分取し、蒞留するこずにより埗られる。
その具䜓䟋を挙げるず、次の劂くである。 セザモヌル酢酞゚ステルの合成 セザモヌル20に無氎酢酞30、燐酞0.2を
加え、宀枩で時間撹拌した埌、䞀倜攟眮する。
æ°Ž100mlを加えお時間撹拌し、分離した有機局
を取り、さらに充分氎掗を行぀た埌、有機局を蒞
留し、Bb83°〜84°0.2mmHgの留分を集めお玄23
のセザモヌル酢酞゚ステルを埗る。 セザモヌルプレニル゚ヌテルの合成 セザモヌル21に苛性゜ヌダ液126を加
えお゜ヌダ塩ずし、これにプレニルクロラむド33
、ベンゞルトリ゚チルアンモニりムクロラむド
を加えお70〜75℃で時間、撹拌還流させ
る。䞀倜攟眮埌、分離した有機局を取り、垌塩
酞、次いで氎で掗浄した埌、蒞留しBb97°〜
100°0.3mmHgの留分を集めお玄18のセザモヌ
ルプレニル゚ヌテルを埗る。 セザモヌルは䞍玔物を含有するずきは、経時的
に暗色化するこずがあるが、その゚ステル及び゚
ヌテル誘導䜓では、経時的倉質はほずんど認めら
れない。たた、セザモヌルずその゚ステル及び゚
ヌテル誘導䜓のチロシナヌれ掻性阻害効果を比范
するず、誘導䜓の方が若干䜎い傟向にあるが、䜿
甚にあた぀おは掻性阻害物効果のみならず、物質
ずしおの安定性、安党性、基材ずの混合性、皮膚
ぞの吞収性等をも勘案しお甚いるのが望たしい。 チロシナヌれ掻性阻害剀ずしおのセザモヌル及
びその誘導䜓の化粧料、医薬品ぞの䜿甚は、基材
ぞの添加量0.01〜重量で甚いるこずができる
が、倚くの堎合、0.01〜0.2重量の添加で充分
な効果が埗られる。 その添加方法は、゚タノヌル、グリセリン、プ
ロピレングリコヌル等の芪氎性溶剀か、トリ゚チ
ルシトレヌト、ベンゞルベンゟ゚ヌト、ゞオクチ
ルフタレヌト等の芪油性溶剀に溶解しお行うが、
基材䞭に既に䞊蚘溶剀類や、油脂、界面掻性材等
のようなセザモヌル及びその誘導䜓を容易に溶解
する成分が混合されおいるずきは盎接添加するこ
ずもできる。 実斜䟋 以䞋に実斜䟋をあげお本発明をさらに詳しく説
明するが、本発明はこれら実斜䟋のみに限定され
るものではない。 実斜䟋  セザモヌル及びその誘導䜓のチロシナヌれ掻性
阻害効果 0.1の−チロシンず0.002の硫酞銅を含有
する0.1芏定リン酞塩緩衝液PH7.02.0mlをず
り、これにセザモヌルたたはその誘導䜓を各々
0.2含有する゚タノヌル溶液を0.05ml加える。
次いで垂販のチロシナヌれシグマケミカル瀟
補、mg圓り500単䜍10mgを0.1芏定リン酞塩緩
衝液PH10mlに溶解した酵玠液を0.05ml加
える。混合物を37℃で60分間振盪した埌、85℃に
分間保持しお反応を止め、0.1芏定リン酞塩緩
衝液PH7.0mlを加えお波長580nの吞光床
ODを枬定し、次匏により、チロシナヌれ反
応の阻害率を求めたずころ、第衚の結果が埗ら
れた。 阻害率−掻性阻害剀添加時のOD−ブラ
ンクOD掻性阻害剀無添加時のOD−ブランクOD×100
INDUSTRIAL APPLICATION FIELD The present invention relates to cosmetics for the purpose of, for example, controlling stains and freckles, preventing sunburn, and treating pigmentation disorders, etc.
This invention relates to tyrosinase activity inhibitors used in pharmaceuticals, etc. BACKGROUND ART Melanin is a black to brown ecological pigment that is said to be produced by oxidative polymerization of tyrosine, and its formation is promoted by the enzyme tyrosinase. The formation of melanin itself is part of the body's defense mechanism, and the well-controlled and uniform formation of melanin is
It is preferable both for maintaining the normal functions of living organisms and from the viewpoint of cosmetics. However, local excessive melanin formation caused by external stimulation such as ultraviolet rays or metabolic abnormalities causes cosmetically unfavorable phenomena such as age spots, freckles, and hyperpigmentation. Although the true cause of such local hypermelaninosis is unknown, the phenomenon is attributed to hyperactivity of the enzyme tyrosinase involved in melanin formation. By inhibiting tyrosinase activity, tyrosinase activity inhibitors suppress such excessive melanin formation and promote whitening of the skin. Utilizing this skin whitening effect, tyrosinase activity inhibitors are used in cosmetics, pharmaceuticals, etc. for the purpose of controlling age spots and freckles, preventing sunburn, and treating hyperpigmentation disorders. Conventionally, crude drug extracts (Japanese Patent Application Laid-Open No. 79033/1983) have been used as tyrosinase activity inhibitors for the purpose of whitening effects.
No. 53-88333, No. 54-2344, No. 57-163307
), mixture of ascorbic acid and crude drug extract (JP-A-52-79032), mixture of ascorbic acid and aloin (JP-A-51-95140), ascorbic acid and 2,4,6-hydroxypropiophenone (Japanese Unexamined Patent Publications No. 51-101138), silk peptide compounds (Unexamined Japanese Patent Application Nos. 57-3827 and 57-40495),
Lipoic acid compounds (JP-A-57-123107), tiopronin-based compounds (JP-A-56-154409), glutathione-based compounds (JP-A-57-134410), pantethine-based compounds (JP-A-56-73012) ), pantetheine compounds (JP-A-57-7405, JP-A No. 59-36606)
No.), trobolone compounds (Japanese Patent Application Laid-open No. 56-26842,
56-147704, 56-147705), chromone compounds (JP-A-55-11410, JP-A-55-143908),
Flavonol compounds (JP-A No. 55-92305, same)
No. 55-111411, No. 55-157580, No. 58-131911
), pyrone compounds (JP-A-53-3538, JP-A No. 57)
-72978, 57-134409), kojic acid compounds (JP-A-53-6432, JP-A-56-7776, JP-A-56-77272)
No. 59-33207), and many others have been disclosed. Problems to be solved by the invention Conventionally known tyrosinase activity inhibitors are:
Some lack efficacy, some seem to have problems with stability and safety, and some are difficult to obtain. There is still no ideal solution that satisfies these requirements. Currently, tyrosinase activity inhibitors, while having excellent efficacy as the first priority, also have stability, safety, and
There is a demand for the emergence of an ideal product that also satisfies economic efficiency. Means for Solving the Problems In order to solve the above problems, the present inventors have extensively searched for substances that inhibit the melanin formation reaction from tyrosine by tyrosinase. , 4-methylenedioxyphenol and its ester derivatives and ether derivatives have been found to be highly effective in inhibiting tyrosinase activity, and have also demonstrated their stability, safety,
After thorough consideration of economic efficiency and the application of its whitening effect to cosmetics, pharmaceuticals, etc., we have confirmed that these compounds can constitute almost ideal tyrosinase activity inhibitors, and have developed the present invention. completed. That is, the present invention is based on the general formula () [In the formula, R is a hydrogen atom, ethyl, n-butyl, n
- from the group consisting of hexyl, cis-3-hexenyl, 2-methoxyethyl, benzyl, phenylethyl, cinnamyl, geranyl, prenyl, retinyl, tocopheryl, rosinyl, acetyl, butyryl, caproyl, oleoyl, benzoyl, cinnamoyl, abiethyl and retinoyl. Indicates at least one selected item. ] A tyrosinase activity inhibitor containing at least one 3,4-methylenedioxyphenol derivative represented by the following as an active ingredient. 3,4-Methylenedioxyphenol (referred to as Cezamol.Hereinafter referred to as Cezamol) has the structural formula of formula () This compound is naturally contained in small amounts in sesame oil along with sezamin, sezamorin, etc., and the purified product is a colorless crystal (melting point: 64°C) with a weak phenolic aroma. Although it is widely known that sezamol has an antioxidant effect, no literature has yet been found that reports that sezamol has an excellent tyrosinase activity inhibitory effect. Sezamol is naturally contained in sesame oil, but since it is in a trace amount, it is not a good idea to separate and purify it, and it is better to obtain sezamol by a synthetic method. Sezamol was synthesized by adding a peracetic acid solution containing a small amount of p-toluenesulfonic acid to piperonal and reacting at room temperature according to the method of Koden et al. [Rec.trav.chim., 55 , 815-20 (1936)]. After cooling, peracetic acid is decomposed with an alkali, unreacted piperonal is removed with a mixture of phenylhydrazine acetic acid, and then solvent extraction is carried out, thereby easily achieving a good yield. A specific example is as follows. Synthesis of Sezamol 420 g of 20% peracetic acid containing a small amount of p-toluenesulfonic acid is slowly added to 150 g of piperonal while stirring while maintaining the internal temperature at 30°C. After the reaction mixture is allowed to stand overnight to complete the reaction, most of the acetic acid is distilled off under reduced pressure. After adding alcoholic potassium hydroxide to decompose peracetic acid, 10 g of phenylhydrazine and 50 g of 4N acetic acid are added to remove unreacted piperonal. After making it acidic by adding dilute sulfuric acid, it is extracted with ether. The ether layer was washed with aqueous sodium bicarbonate and then with water, dried over Glauber's salt, and the ether was distilled off to obtain about 90 g of solid sezamol. This is re-purified from toluene. Sezamol has a phenolic hydroxyl group,
The skin irritation was low, and even when a 12.5% acetone solution of sezamol was applied to shaved guinea pigs, no erythema or redness was observed, and no sensitization was observed. The carboxylic acids that participate in the formation of the ester derivatives of sezamol used as active ingredients in the present invention include aliphatic saturated and unsaturated carboxylic acids such as acetic acid, butyric acid, caproic acid, oleic acid, etc., aromatic carboxylic acids such as benzoic acid, etc. , cinnamic acid, linear and cyclic terpene carboxylic acids, such as rosin acid,
Retinoic acid, etc. Also, the alcohols that participate in the formation of ether derivatives of sezamol include aliphatic saturated and unsaturated alcohols, such as ethanol, butanol, methyl cellosolve, hexenol, prenyl alcohol, aromatic alcohols, such as benzyl alcohol, phenethyl alcohol. etc., linear and cyclic terpene alcohols such as geraniol, retinol, modinol, abietinol, etc. Ester and ether derivatives of sezamol are:
It can be synthesized by conventional methods from sezamol and carboxylic acids or alcohols. For example, sezamol acetate is produced by adding acetic anhydride containing a small amount of phosphoric acid to sezamol, reacting at room temperature, adding water to separate the organic layer, and separating the organic layer.
Obtained by distillation. Sezamol prenyl ether can also be produced by adding prenyl chloride and a small amount of benzyltriethylammonium chloride to sezamol soda salt and stirring and refluxing the mixture for several hours.
It is obtained by separating the organic layer and distilling it.
Specific examples are as follows. Synthesis of sezamol acetate 30 g of acetic anhydride and 0.2 g of phosphoric acid were added to 20 g of sezamol, stirred at room temperature for 7 hours, and then left overnight.
Add 100ml of water, stir for 2 hours, take the separated organic layer, wash thoroughly with water, distill the organic layer, collect a fraction of Bb83°~84°/0.2mmHg,
g of sezamol acetate is obtained. Synthesis of Cezamol Prenyl Ether 126 g of 5% caustic soda solution was added to 21 g of Cezamol to make soda salt, and prenyl chloride 33
g and 5 g of benzyltriethylammonium chloride were added, and the mixture was stirred and refluxed at 70 to 75°C for 7 hours. After standing overnight, the separated organic layer was taken, washed with dilute hydrochloric acid and then water, and then distilled to Bb97° ~
Collect the 100°/0.3 mmHg fraction to obtain about 18 g of sezamol prenyl ether. When sezamol contains impurities, it may darken over time, but its ester and ether derivatives show almost no deterioration over time. Furthermore, when comparing the tyrosinase activity inhibitory effects of sezamol and its ester and ether derivatives, the derivatives tend to be slightly lower; however, when using them, it is important to consider not only the inhibitory effect but also the stability and safety of the substance. It is desirable to use the material by taking into consideration its properties, mixability with the base material, absorption into the skin, etc. Cezamol and its derivatives as tyrosinase activity inhibitors can be used in cosmetics and pharmaceuticals at an addition amount of 0.01 to 5% by weight to the base material, but in most cases, an addition amount of 0.01 to 0.2% by weight is used. A sufficient effect can be obtained. The addition method is by dissolving it in a hydrophilic solvent such as ethanol, glycerin, propylene glycol, or a lipophilic solvent such as triethyl citrate, benzyl benzoate, dioctyl phthalate, etc.
When the base material already contains the above-mentioned solvents, oils and fats, surfactants, and other components that easily dissolve sezamol and its derivatives, they can be added directly. EXAMPLES The present invention will be explained in more detail with reference to Examples below, but the present invention is not limited to these Examples. Example 1 Tyrosinase activity inhibition effect of sezamol and its derivatives Take 2.0 ml of 0.1N phosphate buffer (PH7.0) containing 0.1% L-tyrosine and 0.002% copper sulfate, and add sezamol or its derivatives to this. each
Add 0.05 ml of ethanol solution containing 0.2%.
Next, 0.05 ml of an enzyme solution prepared by dissolving 10 mg of commercially available tyrosinase (manufactured by Sigma Chemical Co., 500 units per mg) in 10 ml of 0.1N phosphate buffer (PH.0) is added. The mixture was shaken at 37°C for 60 minutes, then held at 85°C for 5 minutes to stop the reaction, 2 ml of 0.1N phosphate buffer (PH7.0) was added, and the absorbance (OD) at a wavelength of 580 nm was measured. When the inhibition rate of the tyrosinase reaction was determined using the following formula, the results shown in Table 1 were obtained. Inhibition rate = (1 - OD when active inhibitor is added - blank OD / OD when active inhibitor is not added - blank OD) x 100

【衚】 実斜䟋  メラノヌマ现胞䞭のチロシナヌれ掻性阻害効果 りシ胎児血枅20を含有するむヌグルMEM培
地日本氎産補にメラニン産生腫瘍现胞である
−16メラノヌマ现胞を接皮し、これにセザモヌ
ル、セザモヌルレチノ゚ヌト、セザモヌルレチノ
ヌル゚ヌテルを各々0.2含有するゞメチルスル
ホキシド溶液0.5を添加しお、37℃、炭酞ガス
濃床の条件䞋で、日毎に培地の1/2を曎新
しながら日間培逊した埌、现胞を分離した。 メラニン含有はりむツタヌカヌの方法〔Dev.
Biol.、、99〜1271963〕に埓い、波長400n
における现胞106個圓りの吞光床ODで衚わし
た。たたチロシナヌれ掻性は岩田らの方法
〔Proc.Japan Acad.、56、562〜5671980〕に埓
い、分離した现胞をコヌル酞゜ヌダ0.5を含有
する0.001芏定苛性゜ヌダ液に懞濁し、ホモゞナ
むズしお现胞を砎壊したのち、超高速遠心分離
30000rpm、20分を行い、埗られた䞊柄液に぀
き波長475nにおける现胞106個圓りのΔEmin
ずしお衚わした。 その結果を第衚に瀺す。
[Table] Example 2 Effect of inhibiting tyrosinase activity in melanoma cells B-16 melanoma cells, which are melanin-producing tumor cells, were inoculated into Eagle MEM medium (manufactured by Nippon Suisan) containing 20% fetal bovine serum, and then cezamol, A 0.5% dimethyl sulfoxide solution containing 0.2% each of sezamol retinoate and sezamol retinol ether was added, and 1/2 of the culture medium was refreshed every 2 days at 37°C and a carbon dioxide concentration of 5%. After 6 days of culture, cells were separated. Melanin content was determined by Uitztaker's method [Dev.
Biol., 8 , 99-127 (1963)], wavelength 400 nm.
It was expressed as the optical density (OD) per 10 6 cells. Tyrosinase activity was determined by suspending the separated cells in a 0.001N caustic soda solution containing 0.5% sodium cholate and homogenizing the cells according to the method of Iwata et al. [Proc. Japan Acad., 56 , 562-567 (1980)]. After disrupting the cells, ultra-high-speed centrifugation (30,000 rpm, 20 minutes) was performed, and the resulting supernatant was ΔE/min per 106 cells at a wavelength of 475 nm.
It was expressed as The results are shown in Table 2.

【衚】 第衚より、セザモヌル及びその誘導䜓ずも、
现胞内に吞収され、现胞内でチロシナヌれ掻性阻
害剀ずしお有効に䜜甚しおいるこずが知られる。 実斜䟋  黒色金魚の退色実隓 盎埄30cm、深さ20cmの氎槜、、、に氎
10を入れ、これにセザモヌル、セザモヌルアセ
テヌト、セザモヌルプレニル゚ヌテルの各0.5
゚タノヌル溶液10mlを加え、をコントロヌル
無添加ずしお、各氎槜に黒色出目金尟ず぀
を入れお飌育した。氎槜の氎は日毎に曎新し
た。阻害剀を加えた氎槜䞭の金魚はいずれも週
目頃より退色化し始めた。週目の退色の床合い
及び顕埮鏡芳察による鱗䞭の色玠胞の数の倚少を
第衚に瀺す。
[Table] From Table 2, it can be seen that sezamol and its derivatives
It is known that it is absorbed into cells and acts effectively as a tyrosinase activity inhibitor within the cells. Example 3 Fading experiment on black goldfish Water was placed in tanks A, B, C, and D with a diameter of 30 cm and a depth of 20 cm.
10, and add 0.5% each of cezamol, cezamol acetate, and cezamol prenyl ether.
10 ml of ethanol solution was added, D was used as a control (no additives), and 3 black-eyed gilders were placed in each tank and reared. The water in the aquarium was refreshed every 3 days. All the goldfish in the aquariums to which the inhibitor had been added began to discolor from around the third week. Table 3 shows the degree of discoloration after 6 weeks and the number of chromatophores in the scales as determined by microscopic observation.

【衚】 第衚の結果は、セザモヌル及びその誘導䜓の
皮膚の矎癜効果を充分掚枬させるものであ぀た。 実斜䟋  クリヌム剀 重量 ステアリン酞モノグリセリド 3.5 ステアリン酞 4.7 セチルアルコヌル 1.7 軜質流動パラフむン 14.0 む゜プロピルミリステヌト 3.0 グリセリン 8.0 ステアリルアルコヌル 3.2 ブチルパラベン 0.05 メチルパラベン 0.05 トリ゚タノヌルアミン 0.1 箔 æ°Ž 60.4 50セザモヌル゚タノヌル液 1.0 驙 料 0.3 100.0 䞊蚘凊方䞭、グリセリン、氎、銙料を陀いたも
のを先ず混合し、玄70℃の加熱䞋に十分撹拌混合
し、その枩床に保぀おグリセリン、氎を加え、さ
らによく撹拌混合する。その埌、ゆるやかに撹拌
を続けながら冷华し、玄50℃に䞋぀た段階で銙料
を加え、さらに撹拌を続けながら垞枩たで冷华す
るこずによりクリヌム剀を埗た。 䞊蚘凊方のうち、50セザモヌル゚タノヌル液
の代りに玔氎を甚いる以倖は、䞊蚘ず同様に詊䜜
したクリヌムをブランクずした。たた、䞊蚘凊方
のうち、50セザモヌル゚タノヌル液を陀き、代
りに垂販の日焌け防止剀であるフむルトラゟヌル
−〔Filtrasol−ノルダ瀟米補〕を加
え、玔氎60.4を56.4ずする以倖は、䞊蚘ず同
様に詊䜜したクリヌムを陜性コントロヌルずした
以䞋、察照品ずいう。これらず䞊蚘凊方のセザ
モヌル入りクリヌムをも぀お、日焌けの詊隓を行
な぀た。 䜓重が350〜400のハヌトレヌ軜のモルモツト
匹を甚い、その肩甲骚の毛刈り、剃毛を行な぀
た。cm×cmの陀毛郚を分割し、ここに、
cm×cm角の詊隓区、区をもうけ、そのケ所
にブランクを、残りの぀に䞊蚘凊方のセザモヌ
ル入りクリヌム以䞋、詊隓品ずいうを、さら
に残りの぀に察照品を各々0.02mgcm2になるよ
う塗垃した。資料未塗垃郚分は遮光した。そしお
ナシペナルFL20SEのランプ本をも぀お、10cm
の距離をおいお10分間づ぀照射した総゚ネルギ
ヌ量は1.8ゞナヌルである。 刀定の基準ずしお、照射24時間埌及び、48時間
埌に皮膚に生じた玅斑に぀いお䞋蚘の評点を䞎え
た。なお、浮瘍に぀いおは、党䜓的に極くわづか
しか珟われなか぀たので刀定を行わなか぀た。 評点玅斑の党く認められないもの  僅かな玅斑が認められるもの  明らかな玅斑が認められるもの  䞭等床の玅斑が認められるもの  この評䟡にもずづいた詊隓の結果を第衚に瀺
す。
[Table] The results shown in Table 3 were sufficient to infer the skin whitening effect of sezamol and its derivatives. Example 4 cream agent (weight %) Monoglyceride 3.5 stearic acid 4.7 cethyl alcoholic 1.7 light flow flowing paraphrodes 14.0 isopropyl mirifin 3.0 stear lil alcohol 3.0 stearlil alcohol 3.2 butyl paraben 0.05 methyl paraben 0.05 triet Noamin 05 Trietnol Amin 0. 1 Pure Water 60.4 50 % Cesemall ethanol solution 1.0 Fragrance 0.3 100.0 First, mix the above formulation excluding glycerin, water, and fragrance, heat to about 70°C, stir thoroughly, keep at that temperature, add glycerin and water, and stir and mix further. do. Thereafter, the mixture was cooled with gentle stirring, and when the temperature dropped to about 50°C, a fragrance was added, and the mixture was further cooled to room temperature while stirring to obtain a cream. A cream sample prepared in the same manner as above was used as a blank, except that pure water was used instead of the 50% sezamol ethanol solution in the above formulation. In addition, from the above formulation, excluding the 50% Cezamol ethanol solution, 5% of Filtrasol-A (manufactured by Norda, USA), a commercially available sunscreen, was added instead, and 60.4% of pure water was added. A cream prototyped in the same manner as above was used as a positive control, except that the amount was set to 56.4% (hereinafter referred to as the control product). A sunburn test was conducted using these and a cream containing sezamol with the above formulation. Five Hartley guinea pigs weighing 350 to 400 g were used, and their shoulder blades were shaved and shaved. Divide the 3cm x 3cm hair removal area into 4 parts, and place 1
4 cm x 1 cm square test plots were prepared, two of which were filled with blanks, the remaining one was filled with cream containing sezamol (hereinafter referred to as the test product), and the remaining one was filled with a control product. It was applied at a concentration of 0.02 mg/cm 2 . The unapplied area of the material was shielded from light. And with 5 lamps of National FL20SE, 10cm
The beam was irradiated for 10 minutes at a distance of 10 minutes (total energy amount was 1.8 Joules). As a criterion for evaluation, the following scores were given for erythema that appeared on the skin 24 hours and 48 hours after irradiation. Note that no evaluation was made regarding edema because only a few edema appeared overall. Rating: No erythema at all 0 Slight erythema 1 Obvious erythema 2 Moderate erythema 3 The results of the test based on this evaluation are shown in Table 4.

【衚】 第衚の結果から、セザモヌルが垂販の日焌け
防止剀に比べお非垞に優れた効果玄10分の量
で同等の効果のあるこずがわかる。 実斜䟋  軟 膏 重量 カリテバタヌ 40.0 オリヌブ油 20.0 ミツロり 20.0 パラフむン 19.9 セザモヌル−ブチル゚ヌテル 0.1 100.0 䞊蚘凊方に埓い各成分を混合し、玄70℃に加枩
しおよく撹拌し、充分均䞀にした埌、容噚に流し
蟌み攟冷しお軟膏を぀く぀た。 実斜䟋  化粧氎 重量 ゚タノヌル 20.0 プロピレングリコヌル 5.0 グリセリン 4.5 メチルパラベン 0.1 箔 æ°Ž 70.0 セザモヌルアセテヌト 0.1 驙 料 0.3 100.0 䞊蚘凊方に埓い各成分を混合しお化粧氎を぀く
぀た。 発明の効果 本発明のセザモヌルたたはその゚ステル誘導䜓
あるいぱヌテル誘導䜓を有効成分ずするチロシ
ナヌれ掻性阻害剀は著効性、安定性、安党性、経
枈性等の党おをほが満足し、か぀充分なる矎癜効
果、日焌け防止効果、色玠沈着症治療効果を有す
るものである。
[Table] From the results in Table 4, it can be seen that Sezamol has a much superior effect (same effect with about 1/10th the amount) compared to commercially available sunscreens. Example 5 Ointment (wt%) Carite butter 40.0 Olive oil 20.0 Beeswax 20.0 Paraffin 19.9 Sezamol n-butyl ether 0.1 100.0 Each component was mixed according to the above recipe, heated to about 70°C and stirred well to make it sufficiently uniform. I poured it into a container and left it to cool to make an ointment. Example 6 Lotion (wt%) Ethanol 20.0 Propylene glycol 5.0 Glycerin 4.5 Methylparaben 0.1 Pure water 70.0 Sezamol acetate 0.1 Fragrance 0.3 100.0 A lotion was prepared by mixing each component according to the above recipe. Effects of the Invention The tyrosinase activity inhibitor of the present invention, which contains sezamol or its ester derivative or ether derivative as an active ingredient, substantially satisfies all of the requirements such as excellent efficacy, stability, safety, and economical efficiency, and has sufficient whitening effect. It has a sun protection effect and a pigmentation treatment effect.

Claims (1)

【特蚱請求の範囲】  䞀般匏 〔匏䞭、は氎玠原子、゚チル、−ブチル、
−ヘキシル、シス−−ヘキセニル、−メトキ
シ゚チル、ベンゞル、プニル゚チル、シンナミ
ル、ゲラニル、プレニル、レチニル、トコプリ
ル、アセチル、ブチリル、カプロむル、オレオむ
ル、ベンゟむル、シンナモむル、及びレチノむル
から成る矀より遞ばれたもの少なくずも皮を瀺
す。〕 で衚わされる−メチレンゞオキシプノヌ
ル誘導䜓の少なくずも皮を有効成分ずしお含有
するチロシナヌれ掻性阻害剀。  −メチレンゞオキシプノヌル誘導䜓
の含有量が0.01〜重量である特蚱請求の範囲
第項に蚘茉のチロシナヌれ掻性阻害剀。
[Claims] 1 General formula () [In the formula, R is a hydrogen atom, ethyl, n-butyl, n
- selected from the group consisting of hexyl, cis-3-hexenyl, 2-methoxyethyl, benzyl, phenylethyl, cinnamyl, geranyl, prenyl, retinyl, tocopheryl, acetyl, butyryl, caproyl, oleoyl, benzoyl, cinnamoyl, and retinoyl. Indicates at least one type of thing. ] A tyrosinase activity inhibitor containing at least one 3,4-methylenedioxyphenol derivative represented by the following as an active ingredient. 2. The tyrosinase activity inhibitor according to claim 1, wherein the content of the 3,4-methylenedioxyphenol derivative is 0.01 to 5% by weight.
JP18366084A 1984-09-04 1984-09-04 Inhibitor of tyrosinase activity Granted JPS6163609A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP18366084A JPS6163609A (en) 1984-09-04 1984-09-04 Inhibitor of tyrosinase activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18366084A JPS6163609A (en) 1984-09-04 1984-09-04 Inhibitor of tyrosinase activity

Publications (2)

Publication Number Publication Date
JPS6163609A JPS6163609A (en) 1986-04-01
JPH0369322B2 true JPH0369322B2 (en) 1991-10-31

Family

ID=16139694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18366084A Granted JPS6163609A (en) 1984-09-04 1984-09-04 Inhibitor of tyrosinase activity

Country Status (1)

Country Link
JP (1) JPS6163609A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500824A (en) * 1989-07-25 1992-02-13 むヌストマン コダック カンパニヌ Skin treatment methods to reverse the effects of photoaging
GR1000937B (en) * 1990-08-24 1993-03-16 Eastman Kodak Co Skin treatment and method for the restoration of the skin against sun effects

Also Published As

Publication number Publication date
JPS6163609A (en) 1986-04-01

Similar Documents

Publication Publication Date Title
US5019567A (en) Benzoyl peroxide--quaternary ammonium lipophilic salicylate based pharmaceutical and cosmetic compositions and their use especially in treatment of acne
EP0584191B1 (en) Novel aromatic and polycyclic compounds and their use in human or veterinary medicine and in cosmetics
EP0325540A1 (en) Aromatic esters and thioesters, process for their preparation and their use in human or animal therapeutics and in cosmetics
DE2616479C2 (en) Substituted fluoroacylresorcinols, processes for their preparation and pharmaceuticals and cosmetics containing them
CH671395A5 (en)
DE10244282A1 (en) Preparation with antioxidant properties
US4978523A (en) Melanin inhibitor
EP0832081A1 (en) Bicyclic-aromatic compounds
CH672784A5 (en)
JPWO2014092166A1 (en) Tyrosinase activity inhibitor and whitening agent
JP3636423B2 (en) Cosmetics containing hydrochalcone derivatives as active ingredients
US5158977A (en) Cosmetic and pharmaceutical compositions containing naphthalenol derivatives
JPH0369322B2 (en)
KR100851044B1 (en) 3,5-dihydroxy benzamide derivatives having depigmenting activity and the whitening cosmetic composition containing the same
BG65146B1 (en) Pharmaceutical composition for external application and use thereof as a skin lightening agent or for reducing of human pigmentation
JP4879344B1 (en) Antioxidant polyhydroxybenzene derivative and anti-inflammatory skin external preparation
JPH05105643A (en) Cinnamic acid derivative and skin-beautifying cosmetic containing the derivative as active component
CA1255599A (en) Pharmaceutical compositions containing a 1-substituted methoxy-4-trimethyl-1,2,3,6 benzene derivative
JP3136198B2 (en) Cosmetic or skin composition
JPH05105621A (en) Beautifying cosmetic comprising cinnamic ester derivative as active ingredient
CA1247122A (en) Unsaturated camphor derivatives, and their preparation
JPH11335256A (en) Skin cosmetic
KR20040076112A (en) Whitening composition for external application to the skin containing hydroxy pyranone derivatives
KR102017053B1 (en) NOVEL α-TOCOPHEROL DERIVATIVES, AND COSMETIC USES OF THE SAME
JPH0967225A (en) Skin preparation for external use